Overview

Founded in 1996, Rosetta is an informational genomics company focusing on gene expression technology. Rosetta’s technology platforms are designed to allow researchers to explore the causes and consequences of changes in gene expression and to focus on those cellular processes that are specifically affected by pharmaceuticals, chemicals or genetic engineering.

In May 2001 Merck acquired Rosetta Inpharmatics in a $620 million stock buyout. Rosetta Biosoftware was established as a separate business unit to develop and commercialize the Resolver Expression Data Analysis System. The Rosetta Resolver Gene Expression Data Analysis System became commercially available in June 2000 to meet the demand for high-level gene expression analysis and remains the flagship product of Rosetta BioSoftware. Rosetta Inpharmatics has become a drug discovery unit focusing on analyzing gene data to intelligently select drug targets.

Partners

Rosetta has a strategic partnership agreement with Agilent Technologies Inc. to further develop and commercialize Rosetta's FlexJet DNA microarrays. Agilent made an equity investment in Rosetta.